# SNV4818

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/snv4818
Canonical HTML page: https://getbiobrief.com/entity/snv4818

## Timeline

- **2026-12-31**: Pipeline Integration — Expected completion of the asset transfer and full integration into Novartis's global oncology pipeline.
- **2026-03-20**: Acquisition Announcement — Novartis announces the acquisition of SNV4818 for a total deal value of up to $3 billion.
- **2024-01-15**: Synnovation Development — Synnovation Therapeutics advances SNV4818 through early clinical stages, showing promising medicinal chemistry results.
- **2023-10-01**: Novartis Spin-off — Novartis completes the spin-off of its Sandoz generics division to focus exclusively on innovative medicines.

## Recent coverage (1 stories)

### Novartis Bolsters Oncology Pipeline with $3B Synnovation Breast Cancer Deal
2026-03-20 08:40:18 · Sentiment: Positive · Impact: 8/10 · Sources: 3

Novartis AG has entered into an agreement to acquire SNV4818, an experimental breast cancer drug from Synnovation Therapeutics, in a deal valued at up to $3 billion. This strategic move aims to strengthen Novartis's leadership in the oncology sector as it seeks to replenish its pipeline with high-potential targeted therapies.
Full story: https://getbiobrief.com/story/novartis-synnovation-breast-cancer-acquisition

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.